Disease Landscape and Forecast Insights

Hypertriglyceridemia refers to abnormalities in the concentration of triglycerides in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease and, with very high levels…

Medicare beneficiaries with chronic obstructive pulmonary disease (COPD) have access to more than a dozen long-acting bronchodilator inhalers, ranging from blockbusters like GlaxoSmithKline’s (…

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. A wide array of drugs are available to treat PAH. Phosphodiesterase 5 (PDE…

The chronic obstructive pulmonary disease (COPD) therapy market continues to suffer from the absence of any agents that can reverse disease progression and repair lung tissue. Smoking cessation is…

Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases and is characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first…

TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while newer biologics (i.e., Takeda’s…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs…

MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin; it typically develops in early childhood and can persist into…

MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin, which typically develops in early childhood and can persist…

The systemic sclerosis (SSc) pipeline is replete with therapies targeting pathways underlying autoimmunity, inflammation, and fibrosis, particularly in the early phases of development. Currently,…

Research on the human microbiome is expanding beyond C. difficile, with microbiome-based therapies reaching the clinical trial phase of development for additional disease areas. Investments in this…

The U.S. market for dry eye disease (DED) therapies witnessed notable developments in 2019, including Novartis’s acquisition of Xiidra and the launch of Sun Ophthalmics’ Cequa at a competitive…